CA Market News
6日前
1933 Industries Reports Third Quarter 2026 Financial ResultsJune 29, 2026 5:46 PM
ACCESS NewswireVANCOUVER, BC / ACCESS Newswire / June 29, 2026 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCID:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce its third quarter financial results for the six and nine months ended April 30, 2026 and 2025 ("fiscal 2026"). All amounts expressed are in Canadian dollars.The Company owns 100%1 of Alternative Medicine Association (AMA), the Company's cultivation and production subsidiary centred on the medical and adult-use cannabis market in the state of Nevada.Focusing on quality and value offerings, the Company wholesales cannabis flower, pre-rolls and boutique concentrate products under its proprietary AMA brand to retail accounts across Nevada. AMA branded products consistently rank as top sellers based on volume in the state and the Company is a key supplier in the Las Vegas market.FISCAL 2026 HIGHLIGHTSRevenue of $12.2 MillionGross Profit of $3 MillionGross Margin of 27%Expenses of $3 MillionNet Income of $0.2 MillionRecognized as a top 5 selling cannabis brand in Nevada2FISCAL 2026 AND FISCAL 2025 CONSOLIDATED OPERATING FINANCIAL HIGHLIGHTSRevenueThe Company delivered total revenue of $12,201,267 for fiscal 2026, compared to $13,136,626 for fiscal 2025. Q3 2026 revenue was $4,291,276, compared to $4,730,261 in the prior year comparable period. On a sequential basis, revenue increased by 8.8% to $4,291,276 in Q3 2026 from $3,944,059 in Q2 2026.ExpensesExpenses were $3,123,489 for fiscal 2026, representing a 45.6% decrease from $5,736,539 for fiscal 2025. During Q3 2026, expenses declined to $962,303 from $2,025,619 in the prior-year period. The year-over-year reduction was primarily driven by decreases in interest and tax expenses, and reflects continued disciplined cost management, improved operational execution, and tighter inventory controls.Gross ProfitGross profit was $3,277,581 for fiscal 2026 and gross profit of $5,317,736 for fiscal 2025. The Company generated gross profit of $1,342,714 in the current period compared to gross profit of $2,498,015 in the prior year comparable period. The decline in gross profit reflects sustained pricing pressure and intensified competition from intoxicating hemp products and competition from vertically integrated dispensary brands in the Nevada market.Gross MarginGross margin, calculated as gross profit divided by revenue, was 27% in fiscal 2026 versus 40% in fiscal 2025. Gross margin was 31% in Q3 2026 versus 53% in Q3 2025. The decline in gross profit reflects ongoing margin compression. While margin pressure persists, the Company continues to prioritize strategic pricing, cost reductions, and operational efficiencies to support long-term growth.Net Income/LossThe Company reported net income of $154,092 for fiscal 2026, compared to a net loss of $418,803 in the prior year comparative period, representing a 136.8% improvement year-over-year. Comprehensive income totaled $86,427 for fiscal 2026, an 80.4% improvement from a comprehensive loss of $441,470 in fiscal 2025.MANAGEMENT COMMENTARYThe Company reports strong revenues of $12.2 million for fiscal 2026, amidst a challenging market environment. According to business intelligence and market analytics aggregator Headset, the market has faced notable headwinds, with sales declining 16.9% year-over-year and units sold down 15.2%3. Despite market compression in Nevada, the Company achieved sequential growth of 8.8% compared to Q2 2026, signalling improving momentum and a resilient foothold as a top five, independent brand leader in the state."The Company made substantial progress on cost optimization initiatives during the year, recording a 45.6% reduction from fiscal 2025. The focus on cost reduction and operational efficiencies was also evident at the quarterly level, with Q3 expenses reduced to $0.9 million from $2.0 million in the prior-year period," said Brian Farrell, Chairman and CEO. "The reductions demonstrate management's continued focus on improving efficiency and strengthening the Company's financial foundation. Significantly, the Company returned to profitability in fiscal 2026, reporting net income of $0.2 million compared to a net loss of $0.4 million in the prior year, representing a 136.8% year-over-year improvement. Comprehensive loss also improved significantly, declining by 80.4% to income of $86,427. This reflects the effectiveness of cost reduction measures and points to a sustainable operating model."Ester Vigil, President of 1933 Industries said, "The quarterly report demonstrates disciplined and sustainable operations with improved profitability. We are seeing a swing back to flower this quarter, and with careful planning and tighter inventory management, we are able to deliver flower to our customers with unmatched quality and pricing. The strong execution positions the Company well for enhanced financial performance".The Company is encouraged by impending federal changes related to the regulation of intoxicating hemp products, which are perceived as a primary contributor to the decline in Nevada's legal cannabis sales. The federal Continuing Appropriations and Extensions Act of 2026, signed in late 2025, is expected to redefine "hemp" effective November 2026. This change will effectively prohibit most psychoactive hemp-derived cannabinoids at the federal level, providing a pathway for Nevada regulators to further restrict and phase out these products, which is anticipated to support a more normalized and competitive legal cannabis market.Financial statements are prepared in accordance with IFRS® Accounting Standards issued by the International Accounting Standards Board ("IASB") and the IFRIC® Interpretations of the IFRS Interpretations Committee. Detailed information regarding the Company's financial results as well as management's discussion and analysis can be found at https://sedar.com/ and https://1933industries.com/investors/financial-informationAbout 1933 Industries Inc.1933 Industries is a Nevada-based licensed producer, focused on the cultivation and extraction of a large portfolio of cannabis consumer products in a variety of formats under its flagship brand, Alternative Medicine Association (AMA). Its product offerings are cultivated at the Company's 68,000 sq. ft. indoor facility and marketed directly to retail dispensaries. AMA branded flower, infused pre-rolls, and in-house boutique concentrates consistently rank as the top products sold in Nevada. For more information, please visit www.1933industries.comFor further information please contact:
Alexia Helgason, VP, Investor Relations
604-728-4407
alexia@1933industries.comBrian Farrell, Chairman and CEO
brian@1933industries.comNeither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com. 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.1 As of May 30, 20252 https://www.headset.io/brands/alternative-medicine-association-ama3 https://www.headset.io/markets/nevadaSOURCE: 1933 Industries Inc.View the original press release on ACCESS NewswireOriginal: 1933 Industries Reports Third Quarter 2026 Financial Results
CA Market News
3月前
1933 Industries Reports Second Quarter 2026 Financial ResultsMarch 31, 2026 4:26 PM
ACCESS NewswireVANCOUVER, BC / ACCESS Newswire / March 31, 2026 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCID:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce its second quarter financial results for the three and six months ended January 31, 2026 and 2025 ("fiscal 2026"). All amounts expressed are in Canadian dollars.The Company owns 100%1 of Alternative Medicine Association (AMA), the Company's cultivation and production subsidiary centred on the medical and adult-use cannabis market in the state of Nevada.Focusing on quality and value offerings, the Company wholesales cannabis flower, pre-rolls and boutique concentrate products under its proprietary AMA brand to retail accounts across Nevada. AMA branded products consistently rank as top sellers based on volume in the state and the Company is a key supplier in the Las Vegas market.FISCAL 2026 HIGHLIGHTSRevenue of $7.9 MillionGross Profit of $1.9 MillionGross Margin of 24%Expenses of $2.1 MillionNet Loss of $0.2 millionRecognized as a top 5 selling cannabis brand in Nevada2FISCAL 2026 AND FISCAL 2025 CONSOLIDATED OPERATING FINANCIAL HIGHLIGHTSRevenueTotal revenues were $7.9 million for fiscal 2026 and $8.4 million for fiscal 2025. The decrease in revenues is attributed to ongoing declining flower pricing and market contraction, increased competition from illicit intoxicating hemp products and the slump in tourism, particularly in Las Vegas.ExpensesDuring the reporting period, expenses decreased to $2.1 million compared to $3.7 million in the prior year comparable period. The decrease from the prior year was primarily attributed to lower license taxes and insurance expenses.Gross ProfitThe Company generated gross profit of $1.9 million for fiscal 2026 compared to gross profit of $2.8 million for fiscal 2025. The decrease in gross profit was attributed to lower prices due to market saturation, and aggressive retail dispensary pricing cuts implemented to compete with the resilient illegal market.Gross MarginGross margin calculated as gross profit divided by revenue was 24% in Fiscal 2026 and 34% in Fiscal 2025.Net LossNet loss for fiscal 2026 was $0.2 million and comprehensive loss was $0.5 million. Net loss was $0.89 million and comprehensive loss was $0.7 million in the prior year comparable period.MANAGEMENT COMMENTARYChallenging market conditions in Nevada have negatively impacted revenues and profitability; however, AMA has maintained strong brand positioning with notable performance across both the concentrates and flower categories. According to market intelligence provider Headset, AMA demonstrated a dynamic shift in competitive positioning between November 2025 and February 2026, underscoring resilient demand for its products.In the concentrates category, AMA maintained a strong presence, ranking second in November 2025, fifth in January 2026, and second by February 2026, reflecting sustained consumer interest despite broader market pressures. In the flower category, AMA improved its standing from third in November 2025 to first place by February 2026, indicating growing consumer preference for AMA flower offerings and highlighting the brand's resilience and adaptability within a highly competitive market.The Company is encouraged by impending federal changes related to the regulation of intoxicating hemp products, which are perceived as a primary contributor to the decline in Nevada's legal cannabis sales. The federal Continuing Appropriations and Extensions Act of 2026, signed in late 2025, is expected to redefine "hemp" effective November 2026. This change will effectively prohibit most psychoactive hemp-derived cannabinoids at the federal level, providing a pathway for Nevada regulators to further restrict and phase out these products, which is anticipated to support a more normalized and competitive legal cannabis market.Financial statements are prepared in accordance with IFRS® Accounting Standards issued by the International Accounting Standards Board ("IASB") and the IFRIC® Interpretations of the IFRS Interpretations Committee. Detailed information regarding the Company's financial results as well as management's discussion and analysis can be found at https://sedar.com/ and https://1933industries.com/investors/financial-information1 As of May 30, 2025
2 https://www.headset.io/brands/alternative-medicine-association-amaAbout 1933 Industries Inc.1933 Industries is a Nevada-based licensed producer, focused on the cultivation and extraction of a large portfolio of cannabis consumer products in a variety of formats under its flagship brand, Alternative Medicine Association (AMA). Its product offerings are cultivated at the Company's 68,000 sq. ft. indoor facility and marketed directly to retail dispensaries. AMA branded flower, infused pre-rolls, and in-house boutique concentrates consistently rank as the top products sold in Nevada. For more information, please visit www.1933industries.comFor further information please contact:
Alexia Helgason, VP, Investor Relations
604-728-4407
alexia@1933industries.comBrian Farrell, Chairman and CEO
brian@1933industries.comNeither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com. 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.SOURCE: 1933 Industries Inc.View the original press release on ACCESS NewswireOriginal: 1933 Industries Reports Second Quarter 2026 Financial Results
hdhick
3年前
1933 Industries Reports Fourth Quarter and 2023 Year-End Financial Results and Posts Record Revenues of $18.3 Million
1933 Industries is pleased to announce its fourth quarter ("Q4 2023") and audited annual financial results for the year ended July 31, 2023 ("Fiscal 2023"). All amounts expressed are in Canadian dollars.
The Company owns 91% of Alternative Medicine Association (AMA), the Company’s cultivation and production subsidiary focused on the medical and adult-use cannabis market, and 100% of consumer-packaged goods manufacturer Infused MFG LLC (Infused). The Company’s revenue is derived from wholesale cannabis sales in Nevada (AMA), and from the sale of hemp-derived wellness products (Infused) under the Canna Hemp™ brand sold across the US via e-commerce at cannahemp.com
Management Commentary
“We are pleased to report record revenues of $18.3 million for fiscal 2023, a 46% increase from fiscal 2022”, said Mr. Paul Rosen, Chairman and CEO of the Company. “We are encouraged by this milestone accomplishment, achieved despite experiencing a considerable disruption in our cultivation facility during the 3rd and 4th quarters while the Company upgraded and retrofitted its facility, which significantly reduced overall revenue during those two quarters. With those upgrades now completed, we remain focused on continuing to increase overall revenue, while also remaining committed to fine tuning our operations and continuing to cut costs. We anticipate that our disciplined approach will allow us to pursue additional growth opportunities in the future.”
Fiscal 2023 and 2022 Consolidated Operating Financing Highlights
Total revenues increased by 46% to $18.3 million in fiscal 2023 from $12.5 million in fiscal 2022. AMA revenues increased by 56% during the reporting period, from $10.9 million in fiscal 2022 to $16.8 million in fiscal 2023.
Expenses were $12.8 million for fiscal 2023 compared to $20.2 million for fiscal 2022, including a non-cash goodwill impairment relating to AMA of $4.6 million.
Gross profit, excluding fair value adjustments, was $0.6 million for fiscal 2023, compared to $3.2 million during the same period in fiscal 2022. Gross profit, after fair value adjustments, was a loss of $0.6 million for fiscal 2023 and a profit of $2.7 million for fiscal 2022. The decrease in gross profit was due to increased production and cultivation costs, delayed harvests, and lower yields while the Company upgraded and retrofitted the building’s complex irrigation and humidification systems during the reporting period.
Net loss and adjusted EBITDA were a loss of $14.0 million and $7.6 million, respectively, for fiscal 2023, largely attributed to the infrastructure updates to the cultivation facility, compared to a loss of $18.1 million and $4.8 million, respectively, for fiscal 2022.
Basic and diluted net loss per share was $0.03 for fiscal 2023, compared to $0.04 for fiscal 2022.
Cash was $1.1 million at the end of the reporting period, compared to $0.3 million in fiscal 2022.
Q4 2023 Compared to Q4 2022 Financing Highlights
Q4 2023 revenues increased to $5.6 million from $2.6 million during the comparable period. The 115% increase in revenue in the current period was primarily due to an increase in AMA revenues resulting from the completion of the retrofit and upgrades to the cultivation facility, and from the plant operating at full capacity. AMA generated significant revenue from the sale of whole cannabis flower.
Gross profit was $0.1 million in the current period compared to a gross loss of $1.9 million in the prior year comparable period.
Expenses were $9.2 million in Q4 2023 compared to $2.2 million in Q4 2022. Included in the increase were higher G&A expenses, a $4.6 million goodwill impairment, higher license fees, taxes, insurance, legal and auditing fees, and increased share-based compensation due to the timing of the vesting of previously issued stock options.
Outstanding Debentures
On November 14, 2023, Holders of 10% Senior Unsecured Convertible Debentures Due December 31, 2023, approved a proposed amendment, which authorizes the Company to pursue at its discretion one of the following settlement options:
The extinguishment of the Debentures upon maturity and the principal debt owed thereunder, excluding any interest in arrears, through the issuance of a new 10% unsecured convertible debenture (the “New Debenture”) with a two year maturity, convertible into units at a price of $0.05 per unit, each unit comprising one common share of the Company and one share purchase warrant, subject to certain acceleration provisions as more particularly defined in the indenture governing the New Debenture, or
The extinguishment of the convertible debentures upon maturity, principal debt and excluding interest in arrears, through the issuance of a Unit to the Debenture holders, each Unit being issued at a deemed price of $0.02 per $1.00 of principal, and one share purchase warrant exercisable into one additional common share of the Company at a price of $0.05 for a period of five years from the date of issuance.
As at the date of these financial statements, the Company has not yet determined which settlement option it will choose.
Financial statements are prepared in accordance with International Financial Reporting Standards. Detailed information regarding the Company’s financial results as well as management's discussion and analysis can be found at https://sedar.com/ and https://1933industries.com/investors/financial-information
Please note the next financial release dates in accordance with the continuous disclosure schedule set out by the British Columbia Securities Commission:
2023 Financial Release Dates
Reporting Quarter Release Date
Q1/2024 January 1, 2024
Q2/2024 April 2, 2024
Q3/2024 July 2, 2024
Q4/YE 2024 November 28, 2024
About 1933 Industries Inc.
1933 Industries is a Nevada-based company, focusing on the cultivation and manufacturing of a large portfolio of cannabis consumer-packaged goods in a variety of formats for both the wholesale and retail markets. Its product offerings through its in-house brands include: wholesale flower, pre-rolls, and extracted products under the AMA and Level X brands for the Nevada market; and Canna Hemp™, a national cannabidiol (CBD) brand of wellness products that includes tinctures, gummies, topicals and sports recovery products. The Company owns 91% of Alternative Medicine Association, LC (AMA) and 100% of Infused MFG LLC (Infused). For more information, please visit www.1933industries.com
For further information please contact:
Alexia Helgason, VP, IR, Marketing, Media
604-728-4407
alexia@1933industries.com
birdys3333
5年前
Happy Friday 1933!!! I am into universe signs, lol, so I was bike riding by my dream house, country old fashion house with land, in the hills I bike ride in. And being Youtube man, I am spending lots of time, on videos on manifestation, so today, there was a older gentalmen leaf blow outside his front gate, and it was an electric one, so after riding by, said,,,lets go back and talk to him, well to try and shorten this text, we had a great talk, and he said his family built the house in 1933,,,my dream house, built same year, as the name of my dream company, this dreaming is getting powerful, sweet dreams everyone, something tells me, my heart!!! To like just give it all I got, like a grand fanlly,,,so my advise, hang on to your shares as I will be like going crazy, next week, maybe I start at .06,,,then everyday I move up 3%,,,like forever, lol,,,will think about a plan for Monday:),,,but what ever I come up with, I am sure it will be a perfect one:)